Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

Stock option activity for the three months ended March 31, 2023 is as follows:

	Number of Shares Underlying Outstanding Options	Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—December 31, 2022	2,101,536	$	10.12	7.69	$	8,285
Options exercised	(10,007)	1.88
Options cancelled	(5,864)	40.57
Outstanding—March 31, 2023	2,085,665	$	10.07	7.43	$	7,880
Vested and expected to vest—March 31, 2023	2,085,665	$	10.07	7.43	$	7,880
Exercisable—March 31, 2023	1,353,373	$	9.09	7.42	$	5,385

Schedule of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at March 31, 2023.

		Options Outstanding		Options Exercisable
Exercise Price		Options Outstanding	Weighted Average Remaining Contractual Life (Years)
$	1.85	367,451	7.26	302,928
2.13		879,795	7.49	547,155
14.22		752,408	7.50	454,578
52.40		21,432	6.47	17,768
$	102.60	64,579	8.10	30,944
		2,085,665		1,353,373

Schedule of Nonvested Restricted Stock Units Activity

A summary of RSU activity is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested—December 31, 2022	1,650,815	$	39.83
Granted	2,404,767	12.40
Canceled	(397,969)	16.89
Vested	(568,675)	28.04
Unvested—March 31, 2023	3,088,938	$	23.60

Schedule of Nonvested Restricted Stock Awards Activity

A summary of RSA activity is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested—December 31, 2022	—	$	—
Granted	728,646	15.30
Vested	(305,921)	15.30
Unvested—March 31, 2023	422,725	$	15.30

Schedule of Stock-based Compensation

The Company recognized stock-based compensation expense for all share-based awards in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Cost of revenue	$	774	$	217
Research and development	7,505		3,761
Sales and marketing	2,881		1,524
General and administrative	10,620		3,248
Total stock-based compensation	$	21,780	$	8,750

The following table summarizes stock-based compensation expense by award type (in thousands):

	Three Months Ended March 31,
	2023		2022
RSUs	$	16,330	$	5,901
Stock Options	2,005		2,840
Employee stock purchase plan	184		—
RSAs	3,261		9
Total stock-based compensation	$	21,780	$	8,750